Company Profile

Adenosine Therapeutics LLC
Profile last edited on: 12/20/22      CAGE: 47LR0      UEI: KKPTV97NZX91

Business Identifier: Compounds targeting subtypes of the adenosine receptor
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

Po Box 4632
Charlottesville, VA 22905
   (804) 220-9400
Location: Single
Congr. District: 05
County: Charlottesville city

Public Profile

In 2008, Adenosine was acquired by Clinical Data and, due to various subsequent transactions is now (2019) a division of Allergan PLC. With strong ties originally to the University of Virginia (UVa) in Charlottesville. ATL Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that selectively target the four known adenosine receptor subtypes. Candidates for drug development are identified and screened using the company’s state-of-the-art adenosine receptor screening platform technology. The company was founded with the goal of taking new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include inflammatory indications, sepsis, heart attack, ischemia-reperfusion injury, vascular injury, spinal cord injury, COPD, asthma, diabetes, obesity, inflammatory bowel disease, retinopathy, and Parkinson’s disease. The company’s most advanced drug development program is in Phase III clinical develop

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 2 NIH $1,231,007
Project Title: Safety of A2A Adenosine Agonist for Treatment of Sepsis
2007 2 NIH $1,540,613
Project Title: Antagonist Of A2b Adenosine Receptors For Asthma
2007 1 NIH $104,783
Project Title: Adenosine A2A receptor antagonists for the treatment of cocaine addiction
2006 2 USDA $371,000
Project Title: A2a Adenosine Receptors and Equine Sepsis
2006 1 NIH $122,099
Project Title: A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

Key People / Management

  Robert Capon -- CEO

  Sandra C Abbott -- Director of Operations/Grants Management

  George A Beller

  Robert A Figler -- Director

  William S Gray -- VP, Licensing and Secretary

  Joel Lindel -- Chief Scientific Officer

  Mark D Okusa

  Jayson Michael Rieger

  Ian J Sarembock

  W Scheld

  William Stilley -- Chief Financial Officer

  Robert D Thompson

  Shannon P Williams -- VP, Regulatory & Clinical Development

Company News

There are no news available.